ALNYLAM PHARMACEUTICALS, INC. Increase (Decrease) in Accounts Receivable
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Increase (Decrease) in Accounts Receivable of $142.02 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-07-30
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was -$184.25M, a 409.62% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $399.86M, a 978.03% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for the quarter ending 2025-06-30 was $136.91M.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for the quarter ending 2025-03-31 was $7.43M.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for fiscal 2025 was $359.96M, a 315.90% increase from fiscal 2024.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for fiscal 2024 was $86.55M, a 1.58% decline from fiscal 2023.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for fiscal 2023 was $87.94M, a 92.86% increase from fiscal 2022.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for fiscal 2022 was $45.60M, a 55.21% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $142.02M 10-Q · filed 2026-07-30 | |||
| 2025-12-31 | -$184.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $215.62M derived: sum of 2 quarters · filed 2026-02-12 | $352.53M derived: sum of 3 quarters · filed 2026-07-30 | $359.96M 10-K · filed 2026-02-12 |
| 2025-09-30 | $399.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $536.78M derived: sum of 2 quarters · filed 2026-07-30 | $544.21M 10-Q · filed 2025-10-30 | $603.72M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $136.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $144.35M 10-Q · filed 2026-07-30 | $203.85M derived: sum of 3 quarters · filed 2026-07-30 | $240.95M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $7.43M 10-Q · filed 2025-05-01 | $66.94M derived: sum of 2 quarters · filed 2026-02-12 | $104.03M derived: sum of 3 quarters · filed 2026-02-12 | $94.39M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-12-31 | $59.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $96.60M derived: sum of 2 quarters · filed 2026-02-12 | $86.96M derived: sum of 3 quarters · filed 2026-02-12 | $86.55M 10-K · filed 2026-02-12 |
| 2024-09-30 | $37.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $27.45M derived: sum of 2 quarters · filed 2025-10-30 | $27.04M 10-Q · filed 2025-10-30 | $23.17M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | -$9.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | -$10.05M 10-Q · filed 2025-07-31 | -$13.92M derived: sum of 3 quarters · filed 2026-02-12 | $94.07M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-03-31 | -$410.00K 10-Q · filed 2025-05-01 | -$4.28M derived: sum of 2 quarters · filed 2026-02-12 | $103.71M derived: sum of 3 quarters · filed 2026-02-12 | $106.68M derived: sum of 4 quarters · filed 2026-02-12 |
| 2023-12-31 | -$3.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $104.12M derived: sum of 2 quarters · filed 2026-02-12 | $107.09M derived: sum of 3 quarters · filed 2026-02-12 | $87.94M 10-K · filed 2026-02-12 |
| 2023-09-30 | $107.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $110.96M derived: sum of 2 quarters · filed 2024-10-31 | $91.81M 10-Q · filed 2024-10-31 | $145.08M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-06-30 | $2.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$16.18M 10-Q · filed 2024-08-01 | $37.09M derived: sum of 3 quarters · filed 2025-02-13 | $75.51M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-03-31 | -$19.15M 10-Q · filed 2024-05-02 | $34.12M derived: sum of 2 quarters · filed 2025-02-13 | $72.54M derived: sum of 3 quarters · filed 2025-02-13 | $66.14M derived: sum of 4 quarters · filed 2025-02-13 |
| 2022-12-31 | $53.27M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $91.69M derived: sum of 2 quarters · filed 2025-02-13 | $85.29M derived: sum of 3 quarters · filed 2025-02-13 | $45.60M 10-K · filed 2025-02-13 |
| 2022-09-30 | $38.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $32.02M derived: sum of 2 quarters · filed 2023-11-02 | -$7.67M 10-Q · filed 2023-11-02 | $51.78M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | -$6.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$46.09M 10-Q · filed 2023-08-03 | $13.35M derived: sum of 3 quarters · filed 2024-02-15 | $9.68M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | -$39.70M 10-Q · filed 2023-05-04 | $19.75M derived: sum of 2 quarters · filed 2024-02-15 | $16.08M derived: sum of 3 quarters · filed 2024-02-15 | $51.39M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $59.45M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $55.78M derived: sum of 2 quarters · filed 2024-02-15 | $91.09M derived: sum of 3 quarters · filed 2024-02-15 | $101.80M 10-K · filed 2024-02-15 |
| 2021-09-30 | -$3.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | $31.64M derived: sum of 2 quarters · filed 2022-10-27 | $42.35M 10-Q · filed 2022-10-27 | $63.52M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $35.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-28 | $46.02M 10-Q · filed 2022-07-28 | $67.19M derived: sum of 3 quarters · filed 2023-02-23 | $76.16M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $10.71M 10-Q · filed 2022-04-28 | $31.88M derived: sum of 2 quarters · filed 2023-02-23 | $40.85M derived: sum of 3 quarters · filed 2023-02-23 | $34.06M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $21.17M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $30.14M derived: sum of 2 quarters · filed 2023-02-23 | $23.35M derived: sum of 3 quarters · filed 2023-02-23 | $56.24M 10-K · filed 2023-02-23 |
| 2020-09-30 | $8.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $2.19M derived: sum of 2 quarters · filed 2021-10-28 | $35.07M 10-Q · filed 2021-10-28 | $29.59M derived: sum of 4 quarters · filed 2022-02-10 |
| 2020-06-30 | -$6.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $26.10M 10-Q · filed 2021-08-03 | $20.62M derived: sum of 3 quarters · filed 2022-02-10 | $38.40M derived: sum of 4 quarters · filed 2022-02-10 |
| 2020-03-31 | $32.88M 10-Q · filed 2021-04-29 | $27.40M derived: sum of 2 quarters · filed 2022-02-10 | $45.19M derived: sum of 3 quarters · filed 2022-02-10 | $42.08M derived: sum of 4 quarters · filed 2022-02-10 |
| 2019-12-31 | -$5.48M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-10 | $12.30M derived: sum of 2 quarters · filed 2022-02-10 | $9.20M derived: sum of 3 quarters · filed 2022-02-10 | $24.24M 10-K · filed 2022-02-10 |
| 2019-09-30 | $17.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $14.68M derived: sum of 2 quarters · filed 2020-11-05 | $29.72M 10-Q · filed 2020-11-05 | $45.12M derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-06-30 | -$3.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $11.93M 10-Q · filed 2020-08-06 | $27.33M derived: sum of 3 quarters · filed 2021-02-11 | $27.73M derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-03-31 | $15.04M 10-Q · filed 2020-05-06 | $30.44M derived: sum of 2 quarters · filed 2021-02-11 | $30.84M derived: sum of 3 quarters · filed 2021-02-11 | -$16.97M derived: sum of 4 quarters · filed 2021-02-11 |
| 2018-12-31 | $15.40M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $15.80M derived: sum of 2 quarters · filed 2021-02-11 | -$32.01M derived: sum of 3 quarters · filed 2021-02-11 | -$15.24M 10-K · filed 2021-02-11 |
| 2018-09-30 | $401.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | -$47.41M derived: sum of 2 quarters · filed 2019-10-31 | -$30.64M 10-Q · filed 2019-10-31 | -$11.28M derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-06-30 | -$47.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | -$31.04M 10-Q · filed 2019-08-06 | -$11.68M derived: sum of 3 quarters · filed 2020-02-13 | |
| 2018-03-31 | $16.77M 10-Q · filed 2019-05-02 | $36.12M derived: sum of 2 quarters · filed 2020-02-13 | ||
| 2017-12-31 | $19.36M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $10.67M 10-K · filed 2020-02-13 | ||
| 2017-09-30 | -$8.69M 10-Q · filed 2018-11-07 | |||
| 2016-12-31 | $15.04M 10-K · filed 2019-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |